China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment for the Phase III clinical study of its Category 1 drug LH-1801, in combination with metformin. The study aims to evaluate the efficacy and safety of LH-1801 in treating type 2 diabetes, building on its demonstrated hypoglycemic effects.
LH-1801: Development and Mechanism
LH-1801 is a novel SGLT2 inhibitor co-developed by the Shanghai Institute of Materia Medica (SIMM). The drug works by inhibiting the reabsorption of glucose in the kidneys, thereby lowering blood glucose levels. Preclinical and earlier clinical studies have shown LH-1801 to have a good hypoglycemic effect, positioning it as a potential new treatment option for patients with type 2 diabetes.
Clinical Progress and Future Outlook
The completion of enrollment for the Phase III study is a significant milestone for LH-1801, bringing the drug closer to potential market approval. The study will provide further insights into the drug’s efficacy and safety profile, supporting its development as a new therapeutic option for type 2 diabetes. With the growing prevalence of diabetes globally, LH-1801 aims to address significant unmet medical needs in this area.-Fineline Info & Tech
Leave a Reply